logo-loader

Silence Therapeutics receives further US$2mln under Mallinckrodt deal

Published: 08:11 28 Apr 2021 BST

Silence Therapeutics PLC -

Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said it received a further US$2mln from commercial partner Mallinckrodt under a deal potentially worth up to US$2bn in milestones and royalties.

In 2019, Silence was paid an ‘upfront’ US$20mln for the exclusive worldwide licence to short interfering ribonucleic acids (siRNAs) against one target, C3, and the option to licence siRNAs against two additional targets.

The gene silencing specialist said the latest payment related to development work on the SLN500 C3 targeting programme.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

2 hours, 51 minutes ago